Sullivan: PM is focused on high-income countries. "Is it just cream for the cream?" Fragile State Index: https://t.co/HlCFNzq70S #MAPonco16
4:17am September 24th 2016 via Hootsuite
Sullivan: Shows box/whisker on cancer types, by survival. Breast ca - in India, 30% to 70% spread (!) PM won't cure deltas #MAPonco16
4:16am September 24th 2016 via Hootsuite
Sullivan: There are no linear relationships between scientific progress and cancer outcomes. The problem "we sell it as linear" #MAPonco16
4:14am September 24th 2016 via Hootsuite
Sullivan: Dominant paradigm is drug dev - 79% of all R&D spending on cancer #MAPonco16
4:13am September 24th 2016 via Hootsuite
Sullivan: Hit EU in mid-90's. Society takes time to react; many disciplines involved (Political, Regulatory, Economic, History #MAPonco16
Sullivan: Birch Bayh / Bob Dole amended patent law in 70's to allow universities to gain IP and license it out. '80 in-force #MAPonco16
4:11am September 24th 2016 via Hootsuite
Sullivan: Outline: Context; Economics; and Power. Context is everything: 1960's; public monies; 70's age of worries abt spending #MAPonco16
Sullivan: The individual and society: fundamental questions; de Tocqueville's argument - the individual's need over society's #MAPonco16
4:10am September 24th 2016 via Hootsuite
Sullivan: Cancer: 'pinnacle of the global health mountain'. 'Cancer research is the single largest research endeavor in history' #MAPonco16
4:08am September 24th 2016 via Hootsuite
Richard Sullivan (Kings College, London) Too much, too soon, too fast? #MAPonco16 Health economics.
Live-tweeting today from #MAPonco16 Program: https://t.co/GeIl6pTFA2
4:07am September 24th 2016 via Hootsuite
Ig Nobel prizes: trousers for rats and the truthfulness of liars | The Guardian https://t.co/iZ7ZGw06fp
11:30pm September 23rd 2016 via Hootsuite
Facebook Says It Gave Advertisers Inflated Video Metrics - Bloomberg https://t.co/DGC6umfuwk 3 sec = viewed? Really?!?
10:55pm September 23rd 2016 via Hootsuite
Opposition to Galileo was scientific, not just religious | Aeon Ideas https://t.co/OSwqcxdMYO
9:00pm September 23rd 2016 via Hootsuite
Ig Nobel win for Alpine 'goat man' - BBC News https://t.co/1DBCNb1sSt
8:05pm September 23rd 2016 via Hootsuite
RT @NatureNews: 8 scientists who are among the winners of the 2016 MacArthur 'genius grants' https://t.co/AmztjlaqRt https://t.co/NeMiuhhsKi
7:01pm September 23rd 2016 via Hootsuite
How the FDA Manipulates the Media - Scientific American https://t.co/pyAm9tVML4
6:10pm September 23rd 2016 via Hootsuite
Sotiriou: MINDACT study with MammaPrint '16 NEJM https://t.co/ilZCG1RF63 +/- chemo, underpowered study MAPonco16
12:48pm September 23rd 2016 via Hootsuite
Sotiriou: Optima study comparing GEP for br ca: "broadly equivalent" '16 ref https://t.co/LDNnLNPWxC #MAPonco16
12:44pm September 23rd 2016 via Hootsuite
Sotiriou: Using GHDX's Oncotype, the signature captures high proliferation, resulting in poor prognosis. #MAPonco16
12:41pm September 23rd 2016 via Hootsuite
Sotiriou: With Gene Exp Profiles (GEP) - Put together an online tool 'Adjuvant!' to help define risk https://t.co/rRce03392G #MAPonco16
12:39pm September 23rd 2016 via Hootsuite
Christos Sotiriou (Universite Libre de Bruxelles, Brussels, Belgium): Prediction of relapse #MAPonco16
12:32pm September 23rd 2016 via Hootsuite
Azria: Needing to understand mechanism, technologies needed, improve cost-effectiveness of treatment #MAPonco16
12:29pm September 23rd 2016 via Hootsuite
Azria: In '13 started a new consortium 'Requite' https://t.co/XUAhNohdcz integrate methods, increase PPV https://t.co/kyF5LyxnMy #MAPonco16
12:28pm September 23rd 2016 via Hootsuite
Azria: By using an assay called RILA, was able to show 90% sens but low specificity; working with a MALDI-TOF to increase spec #MAPonco16
12:23pm September 23rd 2016 via Hootsuite
Azria: Shows the complexity of radiotherapy's effects on the system - from this '16 ref https://t.co/U8AeegSiqz #MAPonco16
12:06pm September 23rd 2016 via Hootsuite
Azria: There are ~28.7M cancer survivors; about 50% underwent radiotherapy. Toxicity impairs QoL in survivors #MAPonco16
12:02pm September 23rd 2016 via Hootsuite
David Azria (INSERM, France): Prediction of normal tissue late effect after radiotherapy #MAPonco16
12:01pm September 23rd 2016 via Hootsuite
Easton: Genetic susceptibility - about 60% currently explained, overall for EU population #MAPonco16
11:55am September 23rd 2016 via Hootsuite
Easton: Improving prediction: more SNPs, larger studies; rare var's (WES, WGS), imaging #MAPonco16
11:54am September 23rd 2016 via Hootsuite
Easton: Comb. risk distr. for known risk factors:4% are high risk; of these 18% for br ca; 20% are low risk. BRCA is 0.4% #MAPonco16
Easton: He analysed the commercial test genes here '15 ref https://t.co/wdcObMvPfd and showed a chart of risk est. of genes #MAPonco16
11:50am September 23rd 2016 via Hootsuite
Easton: Shows Myriad's myRisk, Ambry's BreastNext, GeneDx. 'Not much consistency in what these co's offer'. 'Data is rather poor' #MAPonco16
11:48am September 23rd 2016 via Hootsuite
Easton: Risk for all br ca: 9-10%; but first quartile is 18%. ER+ disease, more SNPs, better prediction. Effect of fam history #MAPonco16
11:47am September 23rd 2016 via Hootsuite
Easton: Predom. pathway for br ca by GWAS is FGF signalling. Risk has to use all the var's combined. https://t.co/BHqzEAg8UH #MAPonco16
11:45am September 23rd 2016 via Hootsuite
Easton: Most SNPs are enhancer-enriched; one example of fine-mapping here '16 ref https://t.co/enUXBmkMG3 #MAPonco16
11:44am September 23rd 2016 via Hootsuite
Easton: iCOGS and OncoArray studies, 50K/53K and 60K/88K cases/ctrls, not yet finished yet. #MAPonco16
11:40am September 23rd 2016 via Hootsuite
Easton: Relative risk vs Allele frequency for Br Ca: NBBC genes to the upper left; risk SNPs on the lower right. BRCA1/2 outliers #MAPonco16
11:38am September 23rd 2016 via Hootsuite
Douglas Easton (Cambridge, UK) Risk predictionin breast cancer #MAPonco16
11:37am September 23rd 2016 via Hootsuite
Garraway: A paradox - higher-order combinations are too toxic; new delivery? new dosing? #MAP16
11:06am September 23rd 2016 via Hootsuite
Garraway: Able to show MTAP rescue; effort on PRMT5 depletion, a therapeutic window. Illus. a new method for combinations #MAP16
11:05am September 23rd 2016 via Hootsuite
Garraway: Targeting MTAP loss - perhaps methylosome complex may be a mechanism '16 Science https://t.co/76b0D2He7N #MAP16
11:02am September 23rd 2016 via Hootsuite
Garraway: Expansion of targets = expand combinations. CCLE, Project Achillles: found unexpected synth lethal https://t.co/HrIg98ipKO #MAP16
11:00am September 23rd 2016 via Hootsuite
Garraway: Rational combinations: multiple hits across principles of resistance? Pathway reactivation, pathway-indifferent, etc #MAP16
10:58am September 23rd 2016 via Hootsuite
Garraway: AXL high-state, other genes ID'd; a by-pass model (CREB activation). (RAFi+MEKi resistance conversion states) #MAP16
10:57am September 23rd 2016 via Hootsuite
Garraway: Resistance that they may not see: chart the 'resistome' by transcriptional output. Clusters of MAPK reactivation #MAP16
10:56am September 23rd 2016 via Hootsuite
Garraway: Not really have used this before - exhaustion vs. cytotoxicity. Onto resistance - reviews models of resistance mech's #MAP16
10:54am September 23rd 2016 via Hootsuite
Garraway: T-cell expression in melanoma - subdivided to CD4+ etc. Can see 'high exhaustion at the single-cell level' #MAP16
10:50am September 23rd 2016 via Hootsuite
Garraway: 'Each tumor has single cells that are members of both classes'. MITF vs AXL - becoming a theme across ca types #MAP16
10:49am September 23rd 2016 via Hootsuite
Garraway: Single-cell RNA-seq: fruit salad vs smoothie. BRAF-mutant melanoma '14 ref https://t.co/ysxPg1TmsP bulk cp to single-cell #MAP16
10:48am September 23rd 2016 via Hootsuite
